A focus on PD-L1 in human melanoma
P Hersey, S Gallagher - Clinical Cancer Research, 2013 - AACR
Clinical Cancer Research, 2013•AACR
Abstract Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in
melanoma has been limited by the development of resistance. Combining the BRAF
inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to
BRAF inhibitors also make melanoma cells resistant to immunotherapy? Clin Cancer Res;
19 (3); 514–6.© 2012 AACR.
melanoma has been limited by the development of resistance. Combining the BRAF
inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to
BRAF inhibitors also make melanoma cells resistant to immunotherapy? Clin Cancer Res;
19 (3); 514–6.© 2012 AACR.
Abstract
Treatment of metastatic melanoma with inhibitors of the BRAF V600 oncogene in melanoma has been limited by the development of resistance. Combining the BRAF inhibitors with immunotherapy may prolong the response, but will acquisition of resistance to BRAF inhibitors also make melanoma cells resistant to immunotherapy? Clin Cancer Res; 19(3); 514–6. ©2012 AACR.
AACR
